Samatasvir
Clinical data | |
---|---|
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
|
Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials.[1]
Samatasvir is a highly potent and selective inhibitor of the
NS5A replication complex.[2] While it showed promising results when administered as monotherapy, it is probable that samatasvir would be marketed as a combination product with other anti-hepatitis drugs to increase efficacy and reduce the chance of resistance developing, as with most other novel treatments for hepatitis C currently under development. Trials of samatasvir in combination with other antiviral drugs such as simeprevir are also underway.[3]
See also
References
- PMID 24434503.
- PMID 24867983.
- ^ Clinical trial number NCT01852604 for "Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)" at ClinicalTrials.gov